C
Charles H. Adler
Researcher at Mayo Clinic
Publications - 352
Citations - 33486
Charles H. Adler is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Parkinson's disease & Dementia. The author has an hindex of 77, co-authored 322 publications receiving 27743 citations. Previous affiliations of Charles H. Adler include Banner Health & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
α-Synuclein Locus Triplication Causes Parkinson's Disease
Andrew B. Singleton,Matthew J. Farrer,Joshua C. Johnson,Amanda Singleton,Stephen Hague,Jennifer M. Kachergus,Mary M. Hulihan,Terhi Peuralinna,Amalia Dutra,Robert L. Nussbaum,Sarah Lincoln,Anthony Crawley,Melissa Hanson,Demetrius M. Maraganore,Charles H. Adler,Mark R. Cookson,Manfred D. Muenter,Melisa J. Baptista,David Miller,J. Blancato,John Hardy,Katrina Gwinn-Hardy +21 more
TL;DR: In this article, the α-synuclein was identified as the major component of Lewy bodies, the pathological hallmark of Parkinson's disease, and of glial cell cytoplasmic inclusions.
Journal ArticleDOI
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma,Daniela Berg,Matthew B. Stern,Werner Poewe,C. Warren Olanow,Wolfgang H. Oertel,Jose A. Obeso,Kenneth Marek,Irene Litvan,Anthony E. Lang,Glenda M. Halliday,Christopher G. Goetz,Thomas Gasser,Bruno Dubois,Piu Chan,Bastiaan R. Bloem,Charles H. Adler,Guenther Deuschl +17 more
TL;DR: The Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity, and two levels of certainty are delineated: clinically established PD and probable PD.
Journal ArticleDOI
Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines
Irene Litvan,Jennifer G. Goldman,Alexander I. Tröster,Ben Schmand,Daniel Weintraub,Ronald C. Petersen,Brit Mollenhauer,Charles H. Adler,Karen Marder,Caroline H. Williams-Gray,Dag Aarsland,Jaime Kulisevsky,Maria C. Rodriguez-Oroz,David J. Burn,Roger A. Barker,Murat Emre +15 more
TL;DR: These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage.
Journal ArticleDOI
MDS research criteria for prodromal Parkinson's disease
Daniela Berg,Ronald B. Postuma,Charles H. Adler,Bastiaan R. Bloem,Piu Chan,Bruno Dubois,Thomas Gasser,Christopher G. Goetz,Glenda M. Halliday,Lawrence Joseph,Anthony E. Lang,Inga Liepelt-Scarfone,Irene Litvan,Kenneth Marek,Jose A. Obeso,Wolfgang H. Oertel,C. Warren Olanow,Werner Poewe,Matthew B. Stern,Günther Deuschl +19 more
TL;DR: These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.
Journal ArticleDOI
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Jeffrey H. Kordower,C. Warren Olanow,Hemraj B. Dodiya,Yaping Chu,Thomas G. Beach,Charles H. Adler,Glenda M. Halliday,Raymond T. Bartus +7 more
TL;DR: The extent of nigrostriatal degeneration in patients with Parkinson's disease at different disease durations from time of diagnosis is investigated and loss of dopaminergic markers in the dorsal putamen occurs rapidly and is virtually complete by 4 years post-diagnosis.